anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Myo-inositol is important for glucose homeostasis and has been shown to improve insulin sensitivity. This is a prospective cohort pilot study to determine daily glycemic pharmacokinetics and metabolic influences of myo-inositol supplementation using continuous glucose monitoring system (CGMS) and pre- and post-supplement blood work in high risk pregnancies and women diagnosed with gestational diabetes mellitis (GDM). Risk factors include: obesity, previous pregnancy with GDM, family history of diabetes, glucose intolerance, and polycystic ovarian syndrome (PCOS). Women will have a CGMS device placed on day one and begin with 3 days of placebo plus folic acid (400mcg) to determine baseline glycemia and metabolic levels. For the final 4 days, women with take myo-inositol supplementation (4g) plus folic acid (400mcg). The CGMS device will be removed on day 7 when final blood work will be obtained. Self-capillary glucose testing 4 times per day is recorded to calibrate CGMS glucose values. These observations will help determine the effects of myo-inositol on overall mean glucose and other metabolic factors in high risk and GDM patients, identify pharmacokinetic discipline in pregnancy, and develop the groundwork for future prospective clinical trials for the prevention and/or augmentation in treatment GDM.
The present invention describes a susceptibility locus which is functionally related to asthma. The locus maps within human chromosome 7p15-p14. The invention also describes a novel human gene, GPRA. The invention provides diagnostic methods and materials for analysing allelic variation in said locus and the GPRA gene. The invention also provides polypeptides encoded by GPRA gene and antibodies binding to said polypeptides. The invention further provides pharmaceutical compositions for the treatment of asthma, other IgE-mediated disease, chronic obstructive pulmonary disease or cancer.
This study involves a screening visit with the study physician and a treatment visit. Participants will be asked to complete several questionnaires about their mood during both visits. The treatment visit will involve use of the LFMS device. Participants will place the top of their head inside the device for approximately 20 minutes. Participants will receive either the actual treatment or a sham treatment and will not know which they receive. This device produces weak electromagnetic fields. There is no discomfort or even sensation caused by the device. The device has been declared to be a "non-significant risk device" by the FDA, and there are no known risks associated with its use.
Fatal and severe DIC has been reported in patients receiving GAZYVA for treatment of follicular lymphoma and chronic lymphocytic leukemia. The majority of DIC cases have involved changes in platelets and laboratory coagulation parameters following the first infusion, with spontaneous resolution usually occurring by Day 8. In some cases, DIC was associated with IRRs, TLS, or both [see Adverse Reactions (6.1)]. In patients with suspected DIC, evaluate potential causes, and monitor coagulation parameters, platelet counts, and for signs and symptoms of bleeding or thrombosis. Manage according to standard guidelines for DIC. Supportive care, including transfusion of blood products and other medical management, may be necessary.
Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
The invention relates to a vaginal expansion suppository containing econazole or an econazole salt. The expansion suppository comprises econazole or the econazole salt, a liposolubility matrix and an expansion carrier. When the suppository is fully expanded, a medicinal layer can be in full contact with an inner wall of a vagina, so as to prevent a medicinal liquid from outflowing. The expansion suppository also comprises a tert-butyl hydroxy compound which can prevent econazole from being oxidized so as to improve the stability of econazole. The invention also provides a preparation method and detection methods of the expansion suppository. The vaginal expansion suppository containing econazole or the econazole salt employs seven original leading technologies, and also has the beneficial effects that: the expansion suppository prevents the medicinal liquid from outflowing, has high stability and lasting effect of treatment, and prevents secondary infection.
Actinic granuloma (AG) is a rare dermatological condition with only a few dozen cases reported worldwide. Initially classified as a variant of granuloma annulare, it is now recognized as a distinct entity characterized by asymptomatic annular plaques in sun-exposed areas of the skin. The exact pathogenesis remains unclear, but it is believed to be an inflammatory response to sun damage, possibly involving injured elastic fibers. Numerous local and systemic therapeutic options exist, but no specific treatment guidelines have been established. We present a case of AG treated with intralesional application of triamcinolone acetonide in a 64-year-old male patient. We also discuss the most important clinical and histological characteristics and various treatment options.
Chronic low back pain is among the most important health and economic problems of today. In particular, the success of chronic low back pain treatment with current approaches based on the biomedical care model, which is thought to be synonymous with pain and tissue damage, is limited. It has been demonstrated that tissue damage is not a prerequisite for the development of chronic low back pain. Several studies have shown a strong association between chronic low back pain and psychological factors such as anxiety, fear avoidance, distress/depressed mood, anger, poor coping strategies, and low pain self-efficacy. Despite all this important information and evidence, there is a lack of an overview of the behavioral and emotional factors associated with pain severity, as studies mostly focus on a few major factors. However, the strong interaction between behavioral and emotional factors leads to confusion.

The psychological factors mentioned above are open to discussion, and people with chronic low back pain may experience increased pain severity as a result of emotional processing inadequacy. Baker et al identified five factors for emotional processing deficits related to emotion suppression, unprocessed emotion symptoms, unregulated emotion, avoidance, and poor emotional experience. It is hypothesized that the stated emotional processing deficits have a potential role in the increase in pain severity and development of pain in individuals with chronic low back pain. Therefore, depending on the severity of emotional processing openness, the person may feel pain more than it actually is, exhibit more fear avoidance behavior, and develop negative coping strategies with pain. More recently, Baker et al. argued that the sensation of pain lies at the interface between physical and psychological processes, and therefore, impaired emotional processing may be associated with both psychological factors and physical conditions such as chronic low back pain. However, it is currently unknown whether patients with chronic low back pain process pain sensation differently from asymptomatic individuals. Therefore, behavioral and emotional factors related to pain severity have not been clearly revealed.

The aim of this study is to determine the behavioral and emotional factors associated with pain severity in patients with chronic low back pain.
NEW MATERIAL:A compound expressed by formula I . USE:A synthetic intermediate for ursodeoxycholic acid which is a cholagogue and chenodeoxycholic acid which is a gallstone dissolvent. PREPARATION:For example, the hydroxy group at the 3-position in cholesterol expressed by formula II is acetylated, and the allyl group is oxidized without celaving the double bond at the 5-position to afford a 7-oxo derivative. The 24- position of the resultant compound is then oxidized and cleaved in the presence of trifluoroacetic anhydride, sulfuric acid and hydrogen peroxide to afford a trifluoroacetyloxy compound expressed by formula III (Ac is acetyl), which is then hydrolyzed with potassium carbonate in methanol under heating to give the compound expressed by formula I . The resultant compound is then hydrogenated, oxidized and reduced, etc. to afford ursodeoxycholic acid expressed by formula IV and chenodeoxycholic acid expressed by formula V.
BACKGROUND: Echocardiography-based ultrasomics analysis aids Kawasaki disease (KD) diagnosis but its role in predicting coronary artery lesions (CALs) progression remains unknown. We aimed to develop and validate a predictive model combining echocardiogram-based ultrasomics with clinical parameters for CALs progression in KD.
METHODS: Total 371 KD patients with CALs at baseline were enrolled from a retrospective cohort (cohort 1, n = 316) and a prospective cohort (cohort 2, n = 55). CALs progression was defined by increased Z scores in any coronary artery branch at the 1-month follow-up. Patients in cohort 1 were split randomly into training and validation set 1 at the ratio of 6:4, while cohort 2 comprised validation set 2. Clinical parameters and ultrasomics features at baseline were analyzed and selected for models construction. Model performance was evaluated by area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC) and decision curve analysis (DCA) in the training and two validation sets.
RESULTS: At the 1-month follow-ups, 65 patients presented with CALs progression. Three clinical parameters and six ultrasomics features were selected to construct the model. The clinical-ultrasomics model exhibited a good predictive capability in the training, validation set 1 and set 2, achieving AUROCs of 0.83 (95% CI, 0.75-0.90), 0.84 (95% CI, 0.74-0.94), and 0.73 (95% CI, 0.40-0.86), respectively. Moreover, the AUPRC values and DCA of three model demonstrated that the clinical-ultrasomics model consistently outperformed both the clinical model and the ultrasomics model across all three sets, including the training set and the two validation sets.
CONCLUSIONS: Our study demonstrated the effective predictive capacity of a prediction model combining echocardiogram-based ultrasomics features and clinical parameters in predicting CALs progression in KD.
Participants will receive a high dose of ASP2390 once weekly for a total of 12 doses. The dose for cohort 2 may be adapted after the DEC evaluates emergent safety and tolerability data.
Analgesia is maintained using disposable silicon ballon pump "Accufuser" containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg \& the pump is sufficient for about 60 hours according to patient response.
Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
Point-of-care quantitative analysis of tracing microRNA disease-biomarkers remains a great challenge in the clinical diagnosis. In this paper, we developed a portable fluorescent lateral flow assay for ultrasensitive quantified detection of acute myocardial infarction related microRNAs in bio-samples. SiO2@DQD (bilayer quantum dots assembly with SiO2 core) based fluorescent lateral flow strip was fabricated as the analysis tool. In order to quantify the tracing microRNA in biosamples, a catalytic hairpin assembly and CRISPR/Cas12a cascade amplification method was performed and combined with the fabricated SiO2@DQD lateral flow strip. Thus, our platform gathered double advantages of portability and ultrasensitive quantification. Based on our strips, target myocardial biomarker microRNA-133a can be detected with a detection limit of 0.32 fM, which was almost 1000-fold sensitive compared with previous reported microRNAs-lateral flow strips. Significantly, this portable fluorescent strip can directly detect microRNAs in serum without any pretreatment and PCR amplification steps. When spiked in serum samples, a recovery of 99.65 %-102.38 % can be obtained. Therefore, our method offers a potential tool for ultrasensitive quantification of diseases related microRNA in the point-of-care diseases diagnosis field.
Epilepsy is characterized by the occurrence of epileptic events, ranging from brief bursts of interictal epileptiform brain activity to their most dramatic manifestation as clinically overt bilateral tonic-clonic seizures. Epileptic events are often modulated in a patient-specific way, for example by sleep. But they also reveal temporal patterns not only on ultra- and circadian, but also on multidien scales. Thus, to accurately track the dynamics of epilepsy and to thereby enable and improve personalized diagnostics and therapies, user-friendly systems for long-term out-of-hospital recordings of electrical brain signals are needed. Here, we present two wearable devices, namely ULTEEM and ULTEEMNite, to address this unmet need. We demonstrate how the usability concerns of the patients and the signal quality requirements of the clinicians have been incorporated in the design. Upon testbench verification of the devices, ULTEEM was successfully benchmarked against a reference EEG device in a pilot clinical study. ULTEEMNite was shown to record typical macro- and micro-sleep EEG characteristics in a proof-of-concept study. We conclude by discussing how these devices can be further improved and become particularly useful for a better understanding of the relationships between sleep, epilepsy, and neurodegeneration.
BACKGROUND: To perform a systematic review with meta-analysis with the dual intent of assessing the impact of attaining aggressive vs. conservative beta-lactams PK/PD target on the clinical efficacy for treating Gram-negative infections in critical patients, and of identifying predictive factors of failure in attaining aggressive PK/PD targets.
METHODS: Two authors independently searched PubMed-MEDLINE and Scopus database from inception to 23rd December 2023, to retrieve studies comparing the impact of attaining aggressive vs. conservative PK/PD targets on clinical efficacy of beta-lactams. Independent predictive factors of failure in attaining aggressive PK/PD targets were also assessed. Aggressive PK/PD target was considered a100%fT>4xMIC, and clinical cure rate was selected as primary outcome. Meta-analysis was performed by pooling odds ratios (ORs) extrapolated from studies providing adjustment for confounders using a random-effects model with inverse variance method.
RESULTS: A total of 20,364 articles were screened, and 21 observational studies were included in the meta-analysis (N = 4833; 2193 aggressive vs. 2640 conservative PK/PD target). Attaining aggressive PK/PD target was significantly associated with higher clinical cure rate (OR 1.69; 95% CI 1.15-2.49) and lower risk of beta-lactam resistance development (OR 0.06; 95% CI 0.01-0.29). Male gender, body mass index > 30 kg/m2, augmented renal clearance and MIC above the clinical breakpoint emerged as significant independent predictors of failure in attaining aggressive PK/PD targets, whereas prolonged/continuous infusion administration of beta-lactams resulted as protective factor. The risk of bias was moderate in 19 studies and severe in the other 2.
CONCLUSIONS: Attaining aggressive beta-lactams PK/PD targets provided significant clinical benefits in critical patients. Our analysis could be useful to stratify patients at high-risk of failure in attaining aggressive PK/PD targets.
Due to demographic changes the incidence of older patients with cancer will increase. The complexity of systemic treatment of cancer is also evolving. Older patients with cancer are underrepresented in clinical trials and do often not represent the older population treated in real-world setting. Knowledge on how to treat older patients with cancer is sparse and mostly based on pooled analyses from larger trials including older fit patients. Only few randomised trials include older patients with frailty. Clinical trials dedicated to older or frail patients with cancer are still an unmet need, as argued in this review.
Dyslexia is a specific learning disorder that causes issues related to reading, which affects around 10% of the worldwide population. This can compromise comprehension and memorization skills, and result in anxiety and lack of self-esteem, if no support is provided. Moreover, this support should be highly personalized, to be actually helpful. In this paper, a model to classify the most useful methodologies to support students with dyslexia has been created, with a focus on university alumni. The prediction algorithm is based on supervised machine learning techniques; starting from the issues that dyslexic students experience during their career, it is capable of suggesting customized support digital tools and learning strategies for each of them. The algorithm was trained and tested on data acquired through a self-evaluation questionnaire, which was designed and then spread to more than 1200 university students. It allowed 17 useful tools and 22 useful strategies to be detected. The results of the testing showed an average prediction accuracy higher than 90%, which rises to 94% by renouncing to guess the less-predictable 8 tools/strategies. In the light of this, it is possible to state that the implemented algorithm can achieve the set goal and, thus, reduce the gap between dyslexic and non-dyslexic students. This achievement paves the way for a new modality of facing the problem of dyslexia by university institutions, which aims at modifying teaching activities toward students' needs, instead of simply reducing their study load or duties. This complies with the definition and the aims of inclusivity.
The invention provides a medicament for treating gastric ulcer and a preparation method thereof. A formula of the medicament comprises components of, by weight, 50-250 parts of turmeric, 50-250 parts of purple ginger, 50-250 parts of epigeal srephaia root, 50-250 parts of grass-leaved sweetflag rhizome, 50-250 parts of brassica integrifolia seed, 50-250 parts of dragon ' s blood and 50-330 parts of honey. The medicament can be prepared into a honeyed pill by crushing the five medicinal materials of turmeric, purple ginger, epigeal srephaia root, grass-leaved sweetflag rhizome and brassica integrifolia seed, adding dragon ' s blood, mixing well, adding a proper amount of honey and water, carrying out fanwan, drying at a low temperature, and processing into a honeyed pill. Or the medicament can be prepared into other dosage forms. The medicament of the invention can enhance digesting function of patients, and kill abnormally fermented helicobacter pylori in stomach and intestine, and is capable of relaxing stomach and intestine smooth muscle, alleviating spasm ache, increasing gastric motility, promoting stomach peristalsis and further normalizing stomach digesting function. The medicament has effects of improving stomach microcirculation, promoting blood-supply function of stomach, invigorating blood circulation, scattering stasis, astringing sores, engendering flesh, and protecting gastric mucosa, and can supply sugar and trace elements in time, enable a digestive system to adjust immediately to recover.
This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
The incidence rate of out-of-hospital cardiac arrest (OHCA) is approximately 50 to 100 per 100,000 people. OHCA has a high mortality rate and severe complications that lead to substantial healthcare expenditures. After being resuscitated in the Emergency Department (ED), about one-fifth patients achieve return of spontaneous circulation (ROSC). However, some patients who survive to hospital admission fail to survive. The rate of favorable neurological outcomes is also poor, around 5%. To improve survival rates and neurological outcomes, previous studies focused on understanding the mechanisms of OHCA, identifying risk factors, finding effective interventions, promoting public education, first aid training, and implementing treatments such as targeted temperature management and cardiac catheterization.

OHCA patients experience a postcardiac arrest syndrome (PCAS) between cellular hypoxia and reperfusion, resulting in an inflammatory response in the body. At this stage, patients\' vital signs are typically unstable, and emergency department, including initial post-resuscitation care, rapid stabilization of patients, identification of the cause of OHCA and coordination with appropriate specialists, has a significant impact on post-cardiac arrest short-term outcomes. The timing of ED interventions, including the administration of vasopressors, 12-lead electrocardiography, inotropes, and the time-consuming from ROSC to hospital admission, may also influence short-term outcomes. Currently, there is a lack of comprehensive research on whether ED management affects the short-term outcome in OHCA patients. This study highlights the need to collect and analyze information in this regard.

This study is a retrospective study, a series study in our study team, focusing on a sequential population of nontraumatic adult OHCA patients from January 2016 to August 2023 (2016/1/1\~2023/8/31) at the National Taiwan University Hospital and its three affiliated hospitals, including branches in Hsinchu and Yunlin. The research variables include basic patient information (age, gender, etc.), past medical history, Utstein Style prehospital cardiac arrest patient registry variables (witnessed collapse, bystander CPR, rhythm, defibrillation, medications, airway management, etc.), emergency department management and time intervals (from ROSC to ECG time, from ROSC to CT time), etc. Primary outcomes include survival to hospital admission, 1-day, 3-day, and 7-day survival rates. This study aims to investigate whether the management of the emergency department and time series factors influences the short-term outcomes in patients following OHCA.
Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).